Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: 5

The role of -omics technology in the pathophysiology, diagnosis, and treatment of cardiovascular diseases

Kardiyovasküler hastalıkların fizyopatolojisinde, tanı ve tedavisinde -omik teknolojileri

Pages
470–484
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The recognition and internalization of -omics by clinicians is a time-consuming process, but will be more important in the near future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although evident improvement has occurred in the diagnosis and treatment of cardiovascular disease (CVD), it is still the most important cause of mortality worldwide.
📊
Key Findings & Data:The drugs that were produced 30 years ago are still used in treatment.
💡
Conclusion & Impact:The recognition and internalization of -omics by clinicians is a time-consuming process, but will be more important in the near future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although evident improvement has occurred in the diagnosis and treatment of cardiovascular disease (CVD), it is still the most important cause of mortality worldwide. The majority of the CVDs are multifactorial and polygenic. Therefore, it is logical to use genomics, proteomics, lipidomics, and metabolomics together for diagnosis and effective treatment of CVD. "Genome" is the combination of the words "gene" and "chromosome," and includes all protein-coding genes and intergenic spaces (as well as intragenic regions, or introns, within genes) in an organism. Proteins that are synthesized in a cell, tissue, or organism are all called proteomes. Proteomics is the study of proteomes. The analysis of the lipodome, or all lipids synthesized in the organism, as well as lipidderived mediators, and the functions of these mediators in biological systems, is the field of lipidomics. The metabolome is the complete set of low-molecular-weight metabolites and molecules in a human or any living organism. Metabolomic is the systematic analysis of small molecules and metabolites in human or animal biological fluids. The number of biomarkers used for the purpose of evaluating the risk of cardiovascular events is very limited and many of them are old. The drugs that were produced 30 years ago are still used in treatment. Development of -omics science plays an important role in the search for new biological markers that can be used in the diagnosis of CVD and there is a growing need for advancement of these branches of genetics. The recognition and internalization of -omics by clinicians is a time-consuming process, but will be more important in the near future.

Özet

Kardiyovasküler hastalıklar (KVH) tanı ve tedavidekitüm gelişmelere rağmen, dünya genelinde halen en sık ölümsebebidir. KVH'nın fizyopatolojisi multifaktöryel olup, genetikve çevresel etmenlerin etkileşimi söz konusudur. Bu nedenlegenomik, transkriptomik, proteomik, lipidomik ve metabolomikteknolojilerin tanıda entegre bir şekilde kullanılması, hastalıklarınçok etmenli yapısını anlamamıza ve tedavide etkiliyöntemleri seçmemize yardımcı olacaktır. Gen ve kromozomkelimelerinden türetilen genom, bir organizmadaki proteinkodlayan tüm genleri ve bu genler arasındaki tüm DNA sekanslarını(intronların oluşturduğu boşlukları da içerecek şekilde)ifade etmektedir. Bir hücre, doku ya da organizmadasentezi yapılan proteinlerin tamamı proteom olarak adlandı-rılır. Proteomik ise proteomu inceleyen bilim dalıdır. Lipidombir organizmadaki tüm lipit dizisini ifade etmek için kullanılır;lipidomik vücut sıvı, doku ve hücrelerindeki lipitlerin, lipitlerdenköken alan mediyatörlerin ve biyolojik sistemdeki fonksiyonlarınınınincelenmesini konu alır. Metabolom, bir insandaveya canlı organizmadaki düşük molekül ağırlıklı metabolitveya moleküllerin tamamına denir. Metabolomik insan veyahayvan biyolojik sıvılarındaki küçük moleküllerin ve metabolitlerinsistematik analizidir. Kardiyovasküler olay riskinideğerlendirmek amacı ile kullanılan biyobelirteçlerin sayısıoldukça sınırlıdır ve eski araçlardır. Tedavide hala 30 yıl önceüretilen ilaçlar kullanılmaktadır. KVH tanısında ve tedavisindeyeni ajanların bulunup klinik pratiğe yerleştirilebilmesi için-omik bilimleri önemli yer tutmaktadır ve bu bilim dallarınaolan ihtiyaç artmaktadır. -Omik bilimlerinin klinisyenler tarafındantanınması ve içselleştirilmesi ise zaman alacak bir sü-reçtir ancak bu sürecin hızlanarak devam edeceği ve dahaçok önem kazanacağı söylenebilir.

🔖

Cite This Article

SİNAN, Ü. Y., UNLU, S. (2022). The role of -omics technology in the pathophysiology, diagnosis, and treatment of cardiovascular diseases. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: 5, 470–484. https://ajindex.com/articles/632396

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Annual Meeting, February 6th, 1865. Trans Microsc Soc J 1865;13:16-7
  2. Johannsen W. Elemente der exakten erblichkeitslehre. Deutsche wesentlich erweiterte ausgabe in fünfundzwanig vorlesungen. Smithsonian Institution; 1909
  3. Human Genome Sequencing Consortium I. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-45
  4. Gilbert W. Why genes in pieces? Nature 1978;271:501
  5. Marín-García J. Methodologies in the Era of Cardiovascular "Omics" Post-Genomic Cardiology. Elsevier BV 2014. p. 15-55
  6. Liew C-C, Dzau VJ. The Gene in the Twenty-First Century. Cardiovascular Genetics and Genomics for the Cardiologist. Wiley-Blackwell 2008. p. 1-15
  7. Sanger F. Sequences, Sequences and Sequences. Annu Rev Biochem 1988;57:1-29
  8. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 2009;29:1671-7
  9. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-? signalling response. Nature 2011;470:264-8
  10. Roberts R, Stewart AF. 9p21 and the genetic revolution for coronary artery disease. Clin Chem 2012;58:104-12
  11. Preuss M, König IR, Thompson JR, Erdmann J, Absher D, Assimes TL, et al. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet 2010;3:475-83
  12. Mehta NN. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011;4:465-6
  13. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010;3:256- 66
  14. Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 2011;32:1065-76
  15. Teslovich TM, Musunuru K, Smith A V, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13
  16. Pfeufer